A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Back to Search
Print
Bookmark Trial

NCT00136942

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Langenthal, BE, , Switzerland
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hyperlipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening

- LDL-C < 6.0 mmol/l

- Triglyceride level < 5.0 mmol/l.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy
(LLT) at screening.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

HyperlipidemiaRandomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events NCT02100514
  1. Alexander City, Alabama
  2. Auburn, Alabama
  3. Phoenix, Arizona
  4. Phoenix, Arizona
  5. Tucson, Arizona
  6. Tucson, Arizona
  7. Little Rock, Arkansas
  8. Little Rock, Arkansas
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Norwalk, California
  13. Sacramento, California
  14. Sacramento, California
  15. Santa Rosa, California
  16. Tustin, California
  17. Ventura, California
  18. Aurora, Colorado
  19. Colorado Springs, Colorado
  20. Denver, Colorado
  21. Boca Raton, Florida
  22. Boca Raton, Florida
  23. Brooksville, Florida
  24. Coral Gables, Florida
  25. Fort Lauderdale, Florida
  26. Hialeah, Florida
  27. Hialeah, Florida
  28. Miami Beach, Florida
  29. Miami Lakes, Florida
  30. Miami Lakes, Florida
  31. Miami, Florida
  32. Miami, Florida
  33. Miami, Florida
  34. Miami, Florida
  35. Miami, Florida
  36. Miami, Florida
  37. Miami, Florida
  38. Miramar, Florida
  39. Ocala, Florida
  40. Ocala, Florida
  41. Pembroke Pines, Florida
  42. Pembroke Pines, Florida
  43. Pembroke Pines, Florida
  44. Port Orange, Florida
  45. Port Orange, Florida
  46. Saint Augustine, Florida
  47. Saint Augustine, Florida
  48. Saint Petersburg, Florida
  49. Sarasota, Florida
  50. Tampa, Florida
  51. Boise, Idaho
  52. Avon, Indiana
  53. Augusta, Kansas
  54. Wichita, Kansas
  55. Wichita, Kansas
  56. Wichita, Kansas
  57. Lake Charles, Louisiana
  58. Metairie, Louisiana
  59. Monroe, Louisiana
  60. Bethesda, Maryland
  61. Elkridge, Maryland
  62. Flint, Michigan
  63. Saint Cloud, Minnesota
  64. Saint Cloud, Minnesota
  65. Picayune, Mississippi
  66. Saint Louis, Missouri
  67. Saint Louis, Missouri
  68. Fremont, Nebraska
  69. Portsmouth, New Hampshire
  70. Albuquerque, New Mexico
  71. Greenville, North Carolina
  72. Greenville, North Carolina
  73. Greenville, North Carolina
  74. Hickory, North Carolina
  75. Hickory, North Carolina
  76. Hickory, North Carolina
  77. Raleigh, North Carolina
  78. Raleigh, North Carolina
  79. Dayton, Ohio
  80. Perrysburg, Ohio
  81. Oklahoma City, Oklahoma
  82. Tulsa, Oklahoma
  83. Harleysville, Pennsylvania
  84. Wyomissing, Pennsylvania
  85. Charleston, South Carolina
  86. Columbia, South Carolina
  87. Spartanburg, South Carolina
  88. Germantown, Tennessee
  89. Jackson, Tennessee
  90. Jackson, Tennessee
  91. Knoxville, Tennessee
  92. Carrollton, Texas
  93. Houston, Texas
  94. Houston, Texas
  95. Houston, Texas
  96. Katy, Texas
  97. Missouri City, Texas
  98. Plano, Texas
  99. San Antonio, Texas
  100. Sugar Land, Texas
  101. Orem, Utah
  102. Arlington, Virginia
  103. Norfolk, Virginia
  104. Port Orchard, Washington
  105. Port Orchard, Washington
  106. Walla Walla, Washington
  107. Kenosha, Wisconsin
  108. Manitowoc, Wisconsin
  109. Calgary, Alberta
  110. Burnaby, British Columbia
  111. Kamloops, British Columbia
  112. Kelowna, British Columbia
  113. Langley, British Columbia
  114. New Westminster, British Columbia
  115. Penticton, British Columbia
  116. Vancouver, British Columbia
  117. Victoria, British Columbia
  118. Barrie, Ontario
  119. Brampton, Ontario
  120. Brampton, Ontario
  121. Corunna, Ontario
  122. Etobicoke, Ontario
  123. Markham, Ontario
  124. Newmarket, Ontario
  125. Oakville, Ontario
  126. Oshawa, Ontario
  127. Peterborough, Ontario
  128. Scarborough, Ontario
  129. Thornhill, Ontario
  130. Toronto, Ontario
  131. Toronto, Ontario
  132. Toronto, Ontario
  133. Chicoutimi, Quebec
  134. Greenfield Park, Quebec
  135. Longueuil, Quebec
  136. Montreal, Quebec
  137. Saint-Georges, Beauce, Quebec
  138. Trois-Rivieres, Quebec
  139. Trois-Rivieres, Quebec
  140. Quebec,
  141. Quebec,
  142. Trutnov, Kralovehradecky KRAJ
  143. Praha 10, Vinohrady
  144. Brno,
  145. Brno,
  146. Kladno,
  147. Kladno,
  148. Kromeriz,
  149. Olomouc,
  150. Olomouc,
  151. Olomouc,
  152. Olomouc,
  153. Praha 4,
  154. Praha 4,
  155. Pribram,
  156. Pribram,
  157. Slany,
  158. Slany,
  159. Teplice,
  160. Teplice,
  161. Trutnov,
  162. Lappeenranta,
  163. Turku,
  164. Anyang-si, Gyeonggi-do
  165. Guri-si, Gyeonggi-do
  166. Busan,
  167. Seoul,
  168. Enschede, ER
  169. Amsterdam, North Holland
  170. Apeldoorn,
  171. Eindhoven,
  172. Enschede,
  173. Gorinchem,
  174. Groningen,
  175. Heerlen,
  176. Rotterdam,
  177. Rotterdam,
  178. Sneek,
  179. Tilburg,
  180. Utrecht,
  181. Honefoss,
  182. Oslo,
  183. Oslo,
  184. Lublin, Lubelskie
  185. Zamosc, Lubelskie
  186. Staszow, Swietokrzyskie
  187. Gdynia,
  188. Grodzisk Mazowiecki,
  189. Katowice,
  190. Katowice,
  191. Krakow,
  192. Lodz,
  193. Olawa,
  194. Poznan,
  195. Pulawy,
  196. Warszawa,
  197. Wroclaw,
  198. Wroclaw,
  199. Ponce,
  200. Ponce,
  201. Rio Grande,
  202. Singapore,
  203. Singapore,
  204. Goteborg,
  205. Lessebo,
  206. Linkoping,
  207. Lund,
  208. Lund,
  209. Rattvik,
  210. Stockholm,
  211. Stockholm,
  212. Reading, Berkshire
  213. Salford, Greater Manchester
  214. Glasgow, Lanarkshire Scotland
  215. Chorley, Lancashire
  216. Hexham, Northumberland
  217. Worcester, Worcestershire
  218. Ayr,
  219. Birmingham,
  220. Hull,
  221. Liverpool,
  222. Manchester,
  223. Swansea,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HyperlipidemiaAssess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate NCT00139061
  1. Angers,
  2. Angers,
  3. Bordeaux Cauderan,
  4. Briollay,
  5. Dijon,
  6. Hagondange,
  7. Haut Mauco,
  8. Jarny,
  9. Lille,
  10. Mars LA Tour,
  11. Metz,
  12. Monguilhem,
  13. Mont de Marsan CEDEX,
  14. Mont de Marsan,
  15. Mont de Marsan,
  16. Mont de Marsan,
  17. Moutiers,
  18. Murs Erigne,
  19. Nantes,
  20. Pouilly en Auxois,
  21. Saint Justin,
  22. Saint Martin D'Oney,
  23. Seysses,
  24. Strasbourg,
  25. Thouars,
  26. Tierce,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HyperlipidemiaCompliance With Treatment For Patients With Hyperlipidemia NCT00828945
  1. Akersberga,
  2. Forshaga,
  3. Goteborg,
  4. Goteborg,
  5. Goteborg,
  6. Hoganas,
  7. Jonkoping,
  8. Lessebo,
  9. Lilla Edet,
  10. Limhamn,
  11. Malmo,
  12. Oviken,
  13. Partille,
  14. Stockholm,
  15. Taby,
  16. Trollhattan,
  17. Vasteras,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HyperlipidemiaRandomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events NCT01968954
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Tucson, Arizona
  4. Tucson, Arizona
  5. Encinitas, California
  6. Encinitas, California
  7. Fountain Valley, California
  8. Laguna Hills, California
  9. Laguna Hills, California
  10. North Hollywood, California
  11. San Diego, California
  12. Stockton, California
  13. Tustin, California
  14. Vista, California
  15. Wildomar, California
  16. Colorado Springs, Colorado
  17. Norwalk, Connecticut
  18. Hialeah, Florida
  19. Jacksonville, Florida
  20. Jacksonville, Florida
  21. Miami, Florida
  22. New Smyrna Beach, Florida
  23. Tampa, Florida
  24. Savannah, Georgia
  25. Savannah, Georgia
  26. Evanston, Illinois
  27. Anderson, Indiana
  28. Avon, Indiana
  29. Indianapolis, Indiana
  30. Eunice, Louisiana
  31. Eunice, Louisiana
  32. Quincy, Massachusetts
  33. Minneapolis, Minnesota
  34. Minneapolis, Minnesota
  35. Minneapolis, Minnesota
  36. Missoula, Montana
  37. Cary, North Carolina
  38. Winston Salem, North Carolina
  39. Akron, Ohio
  40. Cleveland, Ohio
  41. Perrysburg, Ohio
  42. Willoughby, Ohio
  43. Oklahoma City, Oklahoma
  44. Ashland, Oregon
  45. Portland, Oregon
  46. Harleysville, Pennsylvania
  47. Philadelphia, Pennsylvania
  48. Wyomissing, Pennsylvania
  49. Charleston, South Carolina
  50. Moncks Corner, South Carolina
  51. Bristol, Tennessee
  52. Corpus Christi, Texas
  53. Houston, Texas
  54. Houston, Texas
  55. Hurst, Texas
  56. Layton, Utah
  57. Norfolk, Virginia
  58. Spokane, Washington
  59. Maroubra, New South Wales
  60. Milton, Queensland
  61. St. Kilda East, Victoria
  62. Chicoutimi, Quebec
  63. Montreal, Quebec
  64. Montreal, Quebec
  65. Quebec City, Quebec
  66. Sherbrooke, Quebec
  67. Victoriaville, Quebec
  68. Hradec Kralove,
  69. Praha 5,
  70. Zlin,
  71. Berlin,
  72. Hannover,
  73. Ludwigshafen,
  74. Schwerin,
  75. Shatin, NT,
  76. Shatin,
  77. Milano, MI
  78. Milano, MI
  79. Milano, MI
  80. Palermo, PA
  81. Roma, RM
  82. Uijeongbu-si, Gyeonggi-do
  83. Gangwon-Do,
  84. Gwangju,
  85. Seoul,
  86. Seoul,
  87. Seoul,
  88. Seoul,
  89. Suwon,
  90. Ulsan,
  91. Katowice, Mazowieckie
  92. Katowice, Slaskie
  93. Gdynia,
  94. Lodz,
  95. Opole,
  96. Oswiecim,
  97. Poznan,
  98. Skierniewice,
  99. Sopot,
  100. Warszawa,
  101. Warszawa,
  102. Warszawa,
  103. Wroclaw,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Official Title  ICMJE A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Brief Summary The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hyperlipidemia
Intervention  ICMJE Drug: Atorvastatin
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: August 25, 2005)		370
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
  • LDL-C < 6.0 mmol/l
  • Triglyceride level < 5.0 mmol/l.

Exclusion Criteria:

  • Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00136942
Other Study ID Numbers  ICMJE A2581089
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP